Evidence map›Paper›PMID 26163103›Full record

ArticleCancer genetics

Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group.

Marijana Vujkovic, Edward F Attiyeh, Rhonda E Ries, Michelle Horn, Elizabeth K Goodman, Yang Ding, Marko Kavcic, Todd A Alonzo, Robert B Gerbing, Betsy Hirsch and 4 more

Open access · greenAbstract read
In one paragraph

Article in Cancer genetics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Marijana VujkovicDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. Electronic address: vujkovicm@email.chop.edu.
Edward F AttiyehDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Rhonda E RiesClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Michelle HornDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Elizabeth K GoodmanDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Yang DingDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Marko KavcicUniversity Medical Centre, Ljubljana, Slovenia.
Todd A AlonzoKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Robert B GerbingChildren's Oncology Group, Monrovia, CA, USA.
Betsy HirschUniversity of Minnesota, Minneapolis, MN, USA.
Susana RaimondiDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Alan S GamisDivision of Hematology/Oncology/Bone Marrow Transplantation, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA.
Soheil MeshinchiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Richard AplencDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Children's Hospital of Philadelphia · USFred Hutch Cancer Center · USChildren's Mercy Hospital · USChildren's Oncology Group · USLjubljana University Medical Centre · SIUniversity of Minnesota · USUniversity of Southern California · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
Genetic Predictors of AML Treatment ResponseR01CA133881 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI APLENC, RICHARD · 2010 to 2014
$2.8M
NCI NIH HHS R01 CA133881NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA98413-08
6 · The paper itself

Abstract

Copy number alterations (CNAs) are a hallmark of pediatric cancer genomes. An increasing number of research groups use multiple platforms and software packages to detect and analyze CNAs. However, different platforms have experimental and analysis-specific biases that may yield different results. We sought to estimate the concordance of CNAs in children with de novo acute myeloid leukemia between two experimental platforms: Affymetrix SNP 6.0 array and Illumina OmniQuad 2.5 BeadChip. Forty-five paired tumor-remission samples were genotyped on both platforms, and CNAs were estimated from total signal intensity and allelic contrast values using the allele-specific copy number analysis of tumors (ASCAT) algorithm. The two platforms were comparable in detection of CNAs, each missing only two segments from a total of 42 CNAs (4.6%). Overall, there was an interplatform agreement of 96% for allele-specific tumor profiles. However, poor quality samples with low signal/noise ratios showed a high rate of false-positive segments independent of the genotyping platform. These results demonstrate that a common analytic pipeline can be utilized for SNP array data from these two platforms. The customized programming template for the preprocessing, data integration, and analysis is publicly available at https://github.com/AplenCHOP/affyLumCNA.

Indexed as

DNA Copy Number VariationsLoss of HeterozygosityAcute DiseaseFemaleGenome-Wide Association StudyGenotypeGenotyping TechniquesHumansLeukemia, MyeloidMaleMicroarray AnalysisPolymorphism, Single Nucleotideacute myeloid leukemiacopy number alterationsPediatricsSNP array

Identifiers

PMID26163103
PMCPMC4523450
OpenAlexW1925577563

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.